Josephus Johannes Fourie

Learn More
Two studies evaluating the efficacy of an imidacloprid/flumethrin collar (Seresto®, Bayer Animal Health, IVP), a deltamethrin collar (Scalibor®, MSD, CP1), a fipronil/(s)-methoprene spot-on (Frontline Combo®, Merial, CP2), a dinotefuran/pyriproxyfen/permethrin spot-on (Vectra 3D®, Ceva, CP3) and an amitraz/fipronil/(s)-methoprene spot-on (Certifect®,(More)
The objectives of the studies listed here were to ascertain the therapeutic and sustained efficacy of 10% imidacloprid (w/w) and 4.5% flumethrin (w/w) incorporated in a slow-release matrix collar, against laboratory-infestations of fleas and ticks on cats. Efficacy was evaluated against the flea Ctenocephalides felis felis, and the ticks Ixodes ricinus,(More)
The studies reported here were conducted to ascertain the efficacy of imidacloprid/flumethrin incorporated in a slow-release matrix collar, against infestations of dogs by fleas, ticks, mites and lice. Efficacy was evaluated against the flea Ctenocephalides felis felis, the ticks Rhipicephalus sanguineus, Ixodes ricinus, Ixodes scapularis, Dermacentor(More)
Canine babesiosis due to Babesia canis is an endemic disease in many European countries. A vaccine is available in some countries, but it does not prevent the infection and just helps in reducing the gravity of clinical signs. Therefore, the major way to help preventing the disease is by controlling tick infestations on dogs. To assess the preventive(More)
The objective of this study was to determine the empirical efficacy of imidacloprid 10 %/flumethrin 4.5 % (Seresto®) collars in preventing long-term transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs. The study was a parallel group design, single centre, randomised, non-blinded, controlled, long-term efficacy study. The(More)
Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight. Three negative controlled, randomized studies were conducted in dogs to evaluate the start to kill (1 study) and the speed of flea kill (2 studies) of(More)
Two experimental studies using a transmission blocking model with Dermacentor reticulatus ticks infected with Babesia canis were performed to test the ability of Effitix® to prevent the transmission of babesiosis in dogs. Four groups of seven dogs (experiment 1) and one group of eight dogs (experiment 2) were treated topically with a novel combination of(More)
The ability of Frontline Tri-Act®/Frontect®, a topical ectoparasiticide containing fipronil and permethrin for dogs, to prevent the transmission of Babesia canis as well as Ehrlichia canis was evaluated by infesting dogs with infected vector ticks. For the Babesia canis study, 16 dogs were randomly allocated to two groups. Eight dogs were treated on day 0(More)
The objective of the study was to determine the sustained effectiveness of 10% imidacloprid (w/w) and 4.5% flumethrin (w/w) incorporated in a slow-release matrix collar in preventing Dipylidium caninum infection in cats following repeated laboratory-infestations with fleas infected with metacestodes. Efficacy against infection with D. caninum was evaluated(More)
Dermacentor reticulatus is a European hard tick of major veterinary importance because it is the vector of canine babesiosis due to Babesia canis. The efficacy against this particular tick species is therefore a key characteristic for an acaricidal solution for dogs. The repellency, prevention of attachment and acaricidal efficacy of Frontline Tri-(More)